Keytruda® (pembrolizumab) – New indication
March 14, 2017 – Merck announced the FDA approval of Keytruda (pembrolizumab) injection, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.
Download PDF
